Description

A synthetic 39-amino-acid dual agonist of the GIP and GLP-1 receptors, lipid-modified for an extended (~5-day) half-life supporting once-weekly research protocols. Its dual incretin action is associated with enhanced insulin sensitivity and appetite/energy-balance effects.

Key research notes:

• Glycemic control in type-2-diabetes trials (SURPASS)
• Body-weight reduction in obesity trials (SURMOUNT-1, NEJM 2022)
• Improvements in insulin sensitivity & adiponectin

Specifications: CAS: 2023788-19-2 · Formula: C₂₂₅H₃₄₈N₄₈O₆₈ · Molar mass: 4813.5 g/mol · Form: Lyophilized powder · Storage: −20 °C (2–8 °C reconstituted)

Reconstitution: Add 2 mL BAC water → 10 mg/mL (2.5 mg = 25 units; 5 mg = 50 units).

Research dosing reference (reported in research, not usage instructions): Reported in trials: subcutaneous once-weekly with slow titration (studied levels 5 / 10 / 15 mg weekly), always under medical supervision starting low. GLP-1/GIP agonists require careful titration — unsupervised use is hazardous.

Research use only. Not for human consumption.